CN116745291A - N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺 - Google Patents

N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺 Download PDF

Info

Publication number
CN116745291A
CN116745291A CN202180084189.5A CN202180084189A CN116745291A CN 116745291 A CN116745291 A CN 116745291A CN 202180084189 A CN202180084189 A CN 202180084189A CN 116745291 A CN116745291 A CN 116745291A
Authority
CN
China
Prior art keywords
alkyl
group
alkoxy
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180084189.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·布拉纳特
B·霍尔姆
M·约翰逊
O·卡尔松
D·L·克纳尔
A·诺德奎斯特
R·J·谢泼德
M·斯旺森
A·汤姆伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN116745291A publication Critical patent/CN116745291A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180084189.5A 2020-12-17 2021-12-16 N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺 Pending CN116745291A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126593P 2020-12-17 2020-12-17
US63/126593 2020-12-17
PCT/IB2021/061839 WO2022130270A1 (en) 2020-12-17 2021-12-16 N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides

Publications (1)

Publication Number Publication Date
CN116745291A true CN116745291A (zh) 2023-09-12

Family

ID=79164845

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180084189.5A Pending CN116745291A (zh) 2020-12-17 2021-12-16 N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺

Country Status (20)

Country Link
US (2) US20240101549A1 (https=)
EP (1) EP4263535A1 (https=)
JP (2) JP7622229B2 (https=)
KR (1) KR20230122080A (https=)
CN (1) CN116745291A (https=)
AR (1) AR124379A1 (https=)
AU (2) AU2021403827B2 (https=)
CA (1) CA3204318A1 (https=)
CL (1) CL2023001763A1 (https=)
CO (1) CO2023008921A2 (https=)
CR (1) CR20230314A (https=)
DO (1) DOP2023000124A (https=)
EC (1) ECSP23053033A (https=)
IL (1) IL303655A (https=)
MX (1) MX2023007287A (https=)
PE (1) PE20232046A1 (https=)
SA (1) SA523441175B1 (https=)
TW (1) TW202239407A (https=)
UY (1) UY39569A (https=)
WO (1) WO2022130270A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4263535A1 (en) * 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
IL317722A (en) * 2022-06-21 2025-02-01 Astrazeneca Ab Solid state forms of N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxamide
JP2025525344A (ja) * 2022-06-21 2025-08-05 アストラゼネカ・アクチエボラーグ Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081701A1 (en) * 2005-09-02 2010-04-01 David Michael Evans FAP inhibitors
CN107106547A (zh) * 2014-10-22 2017-08-29 默沙东公司 作为Janus激酶抑制剂的乙基N‑Boc哌啶基吡唑并吡啶酮
WO2020132661A2 (en) * 2018-12-21 2020-06-25 Praxis Biotech LLC Inhibitors of fibroblast activation protein

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW521072B (en) 1997-06-02 2003-02-21 Meiji Seika Kaisha 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
JP4101053B2 (ja) 2000-08-10 2008-06-11 田辺三菱製薬株式会社 プロリン誘導体及びその医薬用途
JP2003026698A (ja) 2000-09-27 2003-01-29 Tokyo Inst Of Technol 新規化合物、固定化物及び蛋白質のスクリーニング方法
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
JP4184378B2 (ja) 2003-01-31 2008-11-19 株式会社三和化学研究所 ジペプチジルペプチダーゼｉｖを阻害する化合物
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
TWI366438B (en) 2004-08-12 2012-06-21 Ishihara Sangyo Kaisha Fungicidal composition containing acid amide derivative
CA2617715A1 (en) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
EP2099778A2 (en) 2006-11-21 2009-09-16 Smithkline Beecham Corporation Amido anti-viral compounds
AU2011225095C1 (en) 2010-03-11 2017-01-19 Sumitomo Dainippon Pharma Co., Ltd. N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
PL2753334T3 (pl) 2011-08-30 2022-12-12 Trustees Of Tufts College Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
WO2013107820A1 (en) * 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
WO2014016849A2 (en) 2012-07-23 2014-01-30 Sphaera Pharma Pvt. Ltd. Novel triazine compounds
CN104945395B (zh) 2014-03-28 2018-01-23 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
KR20160145803A (ko) 2014-04-22 2016-12-20 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
BR112017004612A2 (pt) 2014-09-10 2018-01-30 Epizyme, Inc. compostos, composição farmacêutica, usos de um composto, e kit
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN108690043B (zh) 2017-04-11 2019-10-18 东莞东阳光科研发有限公司 喹啉类衍生物及其制备方法和用途
EP3612526A2 (en) 2017-04-20 2020-02-26 The Regents of the University of California K-ras modulators
US11584744B2 (en) 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
JP7365332B2 (ja) 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
WO2019084271A1 (en) 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE
US11780821B2 (en) 2017-12-15 2023-10-10 Praxis Biotech LLC Inhibitors of fibroblast activation protein
CN111511729A (zh) 2017-12-19 2020-08-07 默克专利股份公司 Tlr7/8拮抗剂及其用途
EP3749663A1 (en) 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
CA3108099A1 (en) 2018-07-31 2020-02-06 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
ES2991898T3 (es) 2018-08-08 2024-12-05 Sumitomo Pharma Co Ltd Derivado de piperidina con puente ópticamente activo
KR102779601B1 (ko) 2018-08-27 2025-03-12 스미토모 파마 가부시키가이샤 광학 활성인 아자비시클로환 유도체
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
JP7618567B2 (ja) 2019-09-27 2025-01-21 住友ファーマ株式会社 架橋型光学活性２級アミン誘導体
EP4055014B1 (en) 2019-11-06 2025-04-30 Yuhan Corporation PYRROLIDINE AND PIPERIDINE COMPOUNDS
EP4263535A1 (en) * 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081701A1 (en) * 2005-09-02 2010-04-01 David Michael Evans FAP inhibitors
CN107106547A (zh) * 2014-10-22 2017-08-29 默沙东公司 作为Janus激酶抑制剂的乙基N‑Boc哌啶基吡唑并吡啶酮
WO2020132661A2 (en) * 2018-12-21 2020-06-25 Praxis Biotech LLC Inhibitors of fibroblast activation protein

Also Published As

Publication number Publication date
JP2025081297A (ja) 2025-05-27
EP4263535A1 (en) 2023-10-25
CR20230314A (es) 2023-08-18
AU2024219819A1 (en) 2024-10-10
IL303655A (en) 2023-08-01
AU2021403827B2 (en) 2024-07-25
DOP2023000124A (es) 2023-07-09
AU2021403827A1 (en) 2023-07-27
PE20232046A1 (es) 2023-12-27
US11858924B2 (en) 2024-01-02
JP7622229B2 (ja) 2025-01-27
JP2023554405A (ja) 2023-12-27
ECSP23053033A (es) 2023-08-31
AU2021403827A9 (en) 2024-10-17
WO2022130270A1 (en) 2022-06-23
AR124379A1 (es) 2023-03-22
US20240101549A1 (en) 2024-03-28
SA523441175B1 (ar) 2024-08-29
UY39569A (es) 2022-07-29
TW202239407A (zh) 2022-10-16
CA3204318A1 (en) 2022-06-23
US20230312550A1 (en) 2023-10-05
CO2023008921A2 (es) 2023-07-21
CL2023001763A1 (es) 2023-11-17
JP7744538B2 (ja) 2025-09-25
KR20230122080A (ko) 2023-08-22
MX2023007287A (es) 2023-07-03

Similar Documents

Publication Publication Date Title
CN111989321B (zh) Kras g12c抑制剂
AU2019200249B2 (en) Biheteroaryl compounds and uses thereof
WO2020239103A1 (zh) 一种btk抑制剂环衍生物及其制备方法和药学上的应用
KR20220004100A (ko) 안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도
AU2023282477A1 (en) Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use
BRPI0714359A2 (pt) inibidores de pirrolotriazina cinase
JP7744538B2 (ja) Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド
AU2018243691A1 (en) Heterocyclic compound
EP2534151A1 (en) 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
TWI802604B (zh) 嘧啶ＴＢＫ/ＩＫＫε抑制劑化合物及其用途
AU2022214618A1 (en) Cdk2 inhibitors and methods of using the same
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
AU2024205058A1 (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
WO2024125532A1 (zh) 作为CDKs抑制剂的新型并杂环类新化合物及其应用
CN121773101A (zh) 靶向irak蛋白抑制或降解的化合物及其应用
CN112521372B (zh) 一种细胞凋亡蛋白抑制剂及其制备方法和用途
EA048482B1 (ru) N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды
EA051853B1 (ru) N-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)хинолин-4-карбоксамиды
US20260116881A1 (en) Kif modulator compounds and methods of use
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
TW202500141A (zh) 作為ｒｉｐｋ１抑制劑的異㗁唑啶及其用途（二）
HK40053673B (zh) 一种btk抑制剂环衍生物及其制备方法和药学上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination